Approved for INDICATIONS AND USAGE: Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours Safety and efficacy of…
Loading full data from Know Your Drugs Institute…